2022
DOI: 10.1016/j.sapharm.2021.08.003
|View full text |Cite
|
Sign up to set email alerts
|

Evaluating the use of prescription sequence symmetry analysis as a pharmacovigilance tool: A scoping review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
48
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
1
1

Relationship

3
3

Authors

Journals

citations
Cited by 24 publications
(49 citation statements)
references
References 79 publications
1
48
0
Order By: Relevance
“…concluded that PSSA methodology demonstrated only moderate sensitivity and specificity in identifying prescribing cascades and more consistency was required in how these studies were reported. 127 As described previously, similar issues with methodological quality were identified in this systematic review.…”
Section: Principal Findingsmentioning
confidence: 67%
See 2 more Smart Citations
“…concluded that PSSA methodology demonstrated only moderate sensitivity and specificity in identifying prescribing cascades and more consistency was required in how these studies were reported. 127 As described previously, similar issues with methodological quality were identified in this systematic review.…”
Section: Principal Findingsmentioning
confidence: 67%
“…A recent scoping review reported that whilst the PSSA method is a useful tool in detecting prescribing cascades, such cascades need careful clinical review as there is a risk of both false positive and false negative findings. 127 This is particularly problematic when screening for cascades without predefined hypotheses. In our systematic review, the vast majority of included studies (n=94, 93%) examined predefined medications as potentially contributing to a prescribing cascade.…”
Section: Principal Findingsmentioning
confidence: 99%
See 1 more Smart Citation
“…There has been an increasing number of publications using this methodology, with many more presented as conference abstracts that have yet to result in a published manuscript. [4][5][6] The PSSA uses a relatively simple design and computationally efficient approach. 5 Following a case-only design approach, the first step of the PSSA is to identify case-only patients who are those initiated on both an index and marker medication within a pre-specified exposure window (e.g., initiation of a marker drug within 365 days before or after index drug initiation).…”
Section: Introductionmentioning
confidence: 99%
“…Relevant to this research question, it could also be an indicator of inappropriate prescribing, that is, a prescribing cascade where an adverse event is treated with another drug rather than removing the cause for the adverse event. There has been an increasing number of publications using this methodology, with many more presented as conference abstracts that have yet to result in a published manuscript 4–6 …”
Section: Introductionmentioning
confidence: 99%